|
|
Research progress in pharmacogenomics of anesthesia and perioperative period management in enhanced recovery after surgery |
MA Lina1,2 GUO Haiyun2 MA Yumei1,2 NIE Huang2▲ |
1.Graduate School, Air Force Medical University, Shaanxi Province, Xi’an 710000, China;
2.Department of Anesthesia and Perioperative Period Medicine, Xijing Hospital of Air Force Medical University, Shaanxi Province, Xi’an 710000, China |
|
|
Abstract Individualized management of standardized clinical pathways is one of the goals of enhanced recovery after surgery, and drug gene polymorphism is an important genetic factor that causes individual differences in drug response. This review discusses the pharmacogenomics of drugs commonly used during anesthesia and perioperative period. Focusing on analgesics, introduces the gene polymorphism and clinical application of opioid analgesics and non-steroidal anti-inflammatory drugs, and also involves the common drugs involved in anesthesia and perioperative period management such as intravenous anesthesia drugs, inhalation anesthesia drugs, neuromuscular blockers, and antiemetic drugs. The effectiveness and feasibility of using pharmacogenomics to guide individual medicine are demonstrated, and the future research direction is discussed.
|
|
|
|
|
[1] Lyon A,Payne CJ,Mackay GJ. Enhanced recovery programme in colorectal surgery:does one size fit all? [J]. World J Gastroenterol,2012,18(40):5661-5663.
[2] Crews KR,Hicks JK,Pui CH,et al. Pharmacogenomics and individualized medicine:translating science into practice [J]. Clin Pharmacol Ther,2012,92(4):467-475.
[3] Zhang F,Tong J,Hu J,et al. COMT gene haplotypes are closely associated with postoperative fentanyl dose in patients [J]. Anesth Analg,2015,120(4):933-940.
[4] Bastami S,Gupta A,Zackrisson AL,et al. Influence of UGT2B7,OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption [J]. Basic Clin Pharmacol Toxicol,2014,115(5):423-431.
[5] Zhao Z,Lv B,Zhao X,et al. Effects of OPRM1 and ABCB1 gene polymorphisms on the analgesic effect and dose of sufentanil after thoracoscopic-assisted radical resection of lung cancer [J]. Biosci Rep,2019,39(1):BSR20181211.
[6] Tan EC,Lim EC,Teo YY,et al. Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain [J]. Mol Pain,2009,5:32.
[7] Viet CT,Dang D,Aouizerat BE,et al. OPRM1 Methylation Contributes to Opioid Tolerance in Cancer Patients[J]. J Pain,2017,18(9):1046-1059.
[8] Hajj A,Peoc’h K,Laplanche JL,et al. Genotyping test with clinical factors:better management of acute postoperative pain? [J]. Int J Mol Sci,2015,16(3):6298-6311.
[9] Klepstad P,Rakv?覽g TT,Kaasa S,et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease [J]. Acta Anaesthesiol Scand,2004,48(10):1232-1239.
[10] 李力,林峥,徐建伟,等.CYP3A4*1G基因多态性对下腹部手术患者舒芬太尼镇痛效果的影响[J].温州医科大学学报,2016,46(4):258-262.
[11] 陈思,刘瞾宇,曾毅,等.OPRM1 A118G多态性对喉癌患者术后舒芬太尼静脉自控镇痛效果的影响[J].西部医学,2018,30(11):1589-1592.
[12] Stamer UM,Stüber F,Muders T,et al. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication [J]. Anesth Analg,2008, 107(3):926-929.
[13] Naito T,Takashina Y,Yamamoto K,et al. CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone [J]. J Clin Pharmacol,2011,51(11):1529-1538.
[14] Nakagawa M,Kuri M,Kambara N,et al. Dopamine D2 receptor Taq IA polymorphism is associated with postoperative nausea and vomiting [J]. J Anesth,2008,22(4):397-403.
[15] Kolesnikov Y,Gabovits B,Levin A,et al. Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects [J]. Anesth Analg,2011,112(2):448-453.
[16] Sugino S,Hayase T,Higuchi M,et al. Association of μ-opioid receptor gene (OPRM1) haplotypes with postoperative nausea and vomiting [J]. Exp Brain Res,2014, 232(8):2627-2635.
[17] Kapur BM,Lala PK,Shaw JL. Pharmacogenetics of chronic pain management [J]. Clin Biochem,2014,47(13/14):1169-1187.
[18] Eugene AR. CYP2B6 Genotype Guided Dosing of Propofol Anesthesia in the Elderly based on Nonparametric Population Pharmacokinetic Modeling and Simulations [J]. Int J Clin Pharmacol Toxicol,2017,6(1):242-249.
[19] Mour?觔o AL,de Abreu FG,Fiegenbaum M. Impact of the Cytochrome P450 2B6 (CYP2B6) Gene Polymorphism c.516G>T(rs3745274)on Propofol Dose Variability [J]. Eur J Drug Metab Pharmacokinet,2016,41(5):511-515.
[20] Iohom G,Ni Chonghaile M,O’Brien JK,et al. An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia [J]. Eur J Anaesthesiol,2007,24(11):912-919.
[21] Nair AS. Pharmacogenomics of inhalational anesthetic agents [J]. Med Gas Res,2019,9(1):52-53.
[22] Girard T,Suhner M,Levano S,et al. A fulminant malignant hyperthermia episode in a patient with ryanodine receptor gene mutation p.Tyr522Ser [J]. Anesth Analg,2008,107(6):1953-1955.
[23] Lacassie HJ,Nazar C,Yonish B,et al. Reversible nitrous oxide myelopathy and a polymorphism in the gene encoding 5,10-methylenetetrahydrofolate reductase [J]. Br J Anaesth,2006,96(2):222-225.
[24] Feldheiser A,Aziz O,Baldini G,et al. Enhanced Recovery After Surgery (ERAS) for gastrointestinal surgery, part 2: consensus statement for anaesthesia practice [J]. Acta Anaesthesiol Scand,2016,60:289-334.
[25] G?覿tke MR,Bundgaard JR,Viby-Mogensen J. Two novel mutations in the BCHE gene in patients with prolonged duration of action of mivacurium or succinylcholine during anaesthesia [J]. Pharmacogenet Genomics,2007,17(11):995-999.
[26] Mei Y,Wang SY,Li Y,et al. Role of SLCO1B1,ABCB1,and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients [J]. J Clin Pharmacol,2015,55(3):261-268.
[27] 梅杨,杨谧,王春燕,等.OATP1B1基因多态性与罗库溴铵肌松效应的相关性[J].临床麻醉学杂志,2015,31(1):90-92.
[28] Kim MS,Lee JR,Choi EM,et al. Association of 5-HT3B Receptor Gene Polymorphisms with the Efficacy of Ondansetron for Postoperative Nausea and Vomiting [J]. Yonsei Med J,2015,56(5):1415-1420.
[29] Yoshida K,Nishizawa D,Ide S,et al. A pharmacogenetics approach to pain management [J]. Neuropsychopharmacol Rep,2018,38(1):2-8. |
|
|
|